Athyrium Capital Management LP

Search
⚲

Athyrium Capital Management LP ✚
CRD #	161528
SEC #	801-73737
CIK #	0001728001
AUM	2,510.8 M (2026-03-23)
Employees	20 (55% Investors, 0% Brokers)
Phone	212-402-6925
Address	505 Fifth Avenue New York, NY 10017-4920
Source	[IAPD] [EDGAR] [Website] [LinkedIn]

Total AUM ($B) Copy

Sector	Form 13F Holdings	Value ($M)
	Innovative Acquisitions Corp	3.2

Holdings by Sector ($M)

Type	Form D Funds	Date	Sold	AUM
HF	Athyrium Opportunities Fund IV LP	[2021-08-24]	185.0 M	216.5 M
	Filed 2021-12-30 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF	Athyrium Opportunities Fund IV Master Non-US LP	[2021-08-24]	78.2 M	1,270.3 M
	Filed 2021-12-30 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
PE	Athyrium Opportunities IV Co-Invest A LP	2021-08-24		105.3 M
HF	Athyrium Healthcare Strategic Income & Growth IDF LLC	[2017-05-22]	25.2 M	3.1 M
	Filed 2021-01-04 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF	Athyrium Opportunities Fund III LP	[2017-02-15]	255.0 M	197.8 M
	Filed 2016-11-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose
HF	Athyrium Opportunities Fund III Master Non-US LP	[2017-02-15]	150.0 M	496.5 M
	Filed 2016-11-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose
HF	Athyrium Opportunities Fund II-B Master LP	[2015-03-27]	126.3 M	23.0 M
	Offered $126,265,000 · Filed 2015-05-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Net Assets Decline to Disclose
HF	Athyrium Opportunities Fund II LP	[2015-03-27]	419.0 M	76.6 M
	Offered $418,965,000 · Filed 2015-05-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Net Assets Decline to Disclose
HF	Athyrium Opportunities Fund II Master Non-US LP	[2015-03-27]	675.2 M	124.8 M
	Offered $675,250,000 · Filed 2015-05-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Net Assets Decline to Disclose

AUM Breakdown	Accounts	AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals)	0	0.0
(b) Individuals (high net worth individuals)	0	0.0
(c) Banking or thrift institutions	0	0.0
(d) Investment companies	0	0.0
(e) Business development companies	0	0.0
(f) Pooled investment vehicles	12	2.5
(g) Pension and profit sharing plans	0	0.0
(h) Charitable organizations	0	0.0
(i) State or municipal government entities	0	0.0
(j) Other investment advisers	0	0.0
(k) Insurance companies	0	0.0
(l) Sovereign wealth funds and foreign official institutions	0	0.0
(m) Corporations or other businesses not listed above	0	0.0
(n) Other	0	0.0
Total	12	2.5
By Discretionary
Discretionary	12	2.5
Non-Discretionary	0	0.0
Total	12	2.5
By Non-United States Persons
Non-United States Persons		1.9
United States Persons		0.6
Total	12	2.5

Form D Directors	Role	# Filings	# Firms
Elin Strong	Executive Officer	14	3
Jeffrey Ferrell	Executive Officer	21	2
Andrew Hyman	Executive Officer	14	2
Jeremy Lack	Executive Officer	11	2
Paul Wakefield	Executive Officer	11	2
Courtney Paul	Executive Officer	8	2
Rashida Adams	Executive Officer	5	2
Courtney Heizenrader	Executive Officer	3	1

EDGAR Form	CIK	2011 - 2026
13F-HR	[0001728001]
3	[0001728001]
4	[0001728001]
SC 13D	[0001728001]

Form 13D/13G Filer	Form 13D/13G Subject	Filed
Athyrium Capital Management LP	Progenity Inc	[2020-07-06]

Firm Profile (Form ADV)
Discretionary AUM	$0.5B
Serves	Institutional
Fund Types	Hedge Fund, Private Equity

Form 3/4/5 Subject	2011 - 2026
Athyrium Capital Management LP
NB Alternatives Advisers LLC
NB Alternatives GP Holdings LLC
Athyrium Funds GP Holdings LLC
Athyrium Opportunities Advisers LLC
Biora Therapeutics Inc
Ferrell Jeffrey
NB Alternatives Holdings LLC
Athyrium Capital Holdings LLC
Athyrium Opportunities III Acquisition LP

Insider Transaction (Form 3/4/5)	Date	Action	Shares	Price	Value ($)
Biora Therapeutics Inc PROG Warrant · derivative	2021-06-14	Buy	8,097,166	$2.47	20,000,000
Biora Therapeutics Inc PROG Common Stock	2021-06-14	Buy	8,097,166	$2.47	20,000,000
Biora Therapeutics Inc PROG Common Stock	2021-06-01	Buy	961,807	$2.86	2,750,768
Biora Therapeutics Inc PROG Common Stock	2021-06-01	Buy	306,308	$2.86	876,041
Biora Therapeutics Inc PROG 7.25% Convertible Senior Notes due 2025 · derivative	2020-12-07	Buy	78,500,000	$78,500,000.00	6,162,250,000,000,000
Biora Therapeutics Inc PROG Common Stock	2020-12-07	Buy	4,128,440	$3.27	13,499,999
Biora Therapeutics Inc PROG 7.25% Convertible Senior Notes due 2025 · derivative	2020-12-07	Buy	25,000,000	$25,000,000.00	625,000,000,000,000
Biora Therapeutics Inc PROG Common Stock	2020-06-23	Buy	3,333,333	$15.00	49,999,995
Biora Therapeutics Inc PROG Unsecured Convertible Promissory Note · derivative	2020-06-23	Conversion	101,736,263
Biora Therapeutics Inc PROG Series B Preferred Stock · derivative	2020-06-23	Conversion
Biora Therapeutics Inc PROG Common Stock	2020-06-23	Conversion	18,319,853
Biora Therapeutics Inc PROG Common Stock	2020-06-23	Conversion	1,250,000

Comparable Firms	State	AUM
Bedford Ridge Capital LP ✚	NY	2,606.1 M
LL Funds LLC ✚	PA	2,605.2 M
RGM Capital LLC ✚	FL	2,598.3 M
Aventail Capital Group LP ✚	NY	2,551.7 M
Blackstone Ireland Fund Management Limited ✚		2,537.8 M
Owl Creek Asset Management LP ✚	NY	2,468.3 M
CAS Investment Partners LLC ✚	CT	2,447.2 M
Medalist Partners LP ✚	NY	2,442.9 M
Comvest Advisors LLC ✚	FL	2,429.5 M
Oxford Finance Advisors LLC ✚	VA	2,406.9 M

Athyrium Capital Management LP

Assets, Funds, Holdings